Our genomic analyses focusing on PIK3CA-associated cancers and oncogenic “hits” within the PI3K pathway, combined with direct cellular evidence of allele dose-dependent effects of PIK3CAH1047R, adds further support to a revised oncogene model that takes into account the functional implications of allelic imbalances. This evidence concerns the gene PIK3CA and cancer.